Laurus Labs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,812Cr
- +5.3% YoY
- +1.9% QoQ
- Net profit
- ₹282Cr
- +21% YoY
- +11.9% QoQ
- Margin
- 28%
- +4 pp YoY
- +1 pp QoQ
Guidance rank: #58 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand. Laurus Labs expects strong growth in CDMO segment with good year-on-year growth in FY '27, despite possible quarter-to-quarter lumpiness.
From Laurus Labs Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand.
- CDMO revenues are projected to grow to 50% of total sales by FY2030, indicating significant expansion in this segment.
- The Affordable Medicines division (formerly Generics) showed strong 18% growth in FY26, with steady business outlook.
- Fluctuations quarter-to-quarter possible, but overall growth momentum is expected to be maintained, especially in CDMO.
- New fermentation and formulation capacities coming online will support volume expansion.
2 more points from Laurus Labs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Laurus Labs is investing in new modalities including cell culture, precision fermentation, enzymes, biocatalysis, cell therapy, gene therapy, and ADCs as a strategic focus (Page 17).
- A new greenfield capex of 500 acres in Atchutapuram is planned; more details to be shared next quarter (Page 17).
- Capex increased from INR 1,000 crores annually to INR 1,500 crores annually, reflecting growth and with good visibility into product and customer demand (Page 16).
2 more points from Laurus Labs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Laurus Labs has a strong order book for the next year, ensuring continued growth.
- Visibility exists for commercialization of some CDMO programs in FY '27, but due to clinical uncertainties, exact timing is hard to predict.
- Orders are diversified across multiple products, minimizing concentration and destocking risks.
2 more points from Laurus Labs Ltd's call on order book
Create a free account to keep reading this call
Laurus Labs Ltd — Quarterly revenue & net profit
Laurus Labs Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,812 | 1,720 | +5.3% | 1,778 | +1.9% |
| Operating profit (EBITDA) | 512 | 421 | +21.6% | 480 | +6.7% |
| Operating margin | 28% | 24% | +4 pp | 27% | +1 pp |
| Profit before tax | 361 | 312 | +15.7% | 327 | +10.4% |
| Net profit (PAT) | 282 | 233 | +21% | 252 | +11.9% |
| EPS (₹) | 5.17 | 4.33 | +19.4% | 4.66 | +10.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.2K Cr, net profit ₹436 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Laurus Labs Ltd Q4 FY26 results?
Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand. Laurus Labs expects strong growth in CDMO segment with good year-on-year growth in FY '27, despite possible quarter-to-quarter lumpiness.
What is Laurus Labs Ltd share price analysis?
Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 96.6 with a market cap of ₹105,577 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs Ltd planning capital expenditure?
Laurus Labs is investing in new modalities including cell culture, precision fermentation, enzymes, biocatalysis, cell therapy, gene therapy, and ADCs as a strategic focus (Page 17).
Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
